<DOC>
	<DOCNO>NCT02031601</DOCNO>
	<brief_summary>Objective : To compare efficacy safety chemotherapy plus intercalated EGFR-tyrosine kinase inhibitor ( TKI ) combination therapy TKI alone therapy first-line treatment patient non-small-cell lung cancer ( NSCLC ) . Methods : Patients untreated , stage IIIB/IV , EGFR mutation-positive NSCLC randomly assign combination therapy group ( receive four cycle docetaxel pemetrexed ( day 1 ) plus platinum ( day 1 ) intercalate TKI ( gefitinib , erlotinib Icotinib , day 2-15 ) every 3 week ) TKI alone therapy ( gefitinib , erlotinib Icotinib , daily ) . All patient continue receive TKI progression unacceptable toxicity death . The primary endpoint progression-free survivial ( PFS ) . Expected result : PFS combination therapy group prolong nineteen month PFS TKI alone therapy group ten month . Overall survival ( OS ) combination therapy group prolong 36 month OS TKI alone therapy group 26 month . Hypothesis : Platinum-based chemotherapy plus intercalated TKI combination therapy first-line treatment prolong PFS OS patient NSCLC .</brief_summary>
	<brief_title>Intercalated Combination Chemotherapy Tyrosine Kinase Inhibitors First-line Treatment Patients With Non-Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Adult patient , &gt; =18 year age ; Advanced ( stage IIIB/IV ) nonsmallcell lung cancer ; Although stageⅠⅢA , contraindication surgery ; EGFR mutationpositive ( EGFR exon18 , exon19 exon21 ) ; Measurable disease ; ECOG Performance Status 0 1 2 . Wildtype EGFR ; Prior exposure agent direct HER axis ; Prior chemotherapy systemic antitumor therapy advance disease ; Unstable systemic disease ; Any malignancy within last 5 year , except cure basal cell cancer skin cure cancer situ cervix ; Brain metastasis spinal cord compression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>